These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9790157)

  • 21. Short onset of action of a serotonin reuptake inhibitor when used to reduce premenstrual irritability.
    Landén M; Erlandsson H; Bengtsson F; Andersch B; Eriksson E
    Neuropsychopharmacology; 2009 Feb; 34(3):585-92. PubMed ID: 18596686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.
    Freeman EW
    CNS Drugs; 2004; 18(7):453-68. PubMed ID: 15139800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo.
    Landén M; Eriksson O; Sundblad C; Andersch B; Naessén T; Eriksson E
    Psychopharmacology (Berl); 2001 May; 155(3):292-8. PubMed ID: 11432692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial.
    Schmidt PJ; Grover GN; Rubinow DR
    Arch Gen Psychiatry; 1993 Jun; 50(6):467-73. PubMed ID: 8498881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial.
    Sundström I; Bäckström T
    Psychoneuroendocrinology; 1998 Jan; 23(1):73-88. PubMed ID: 9618754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A placebo-controlled study of the effects of L-tryptophan in patients with premenstrual dysphoria.
    Steinberg S; Annable L; Young SN; Liyanage N
    Adv Exp Med Biol; 1999; 467():85-8. PubMed ID: 10721042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased premenstrual dosing of nefazodone relieves premenstrual magnification of depression.
    Miller MN; Miller BE; Chinouth R; Coyle BR; Brown GR
    Depress Anxiety; 2002; 15(1):48-51. PubMed ID: 11816054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial.
    Guelfi JD; Strub N; Loft H
    J Affect Disord; 2000 Jun; 58(3):201-9. PubMed ID: 10802128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group.
    Thys-Jacobs S; Starkey P; Bernstein D; Tian J
    Am J Obstet Gynecol; 1998 Aug; 179(2):444-52. PubMed ID: 9731851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria.
    Eriksson E
    Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S27-33. PubMed ID: 10471170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paroxetine as a treatment for premenstrual dysphoric disorder.
    Yonkers KA; Gullion C; Williams A; Novak K; Rush AJ
    J Clin Psychopharmacol; 1996 Feb; 16(1):3-8. PubMed ID: 8834412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of kleptomania correlating with premenstrual dysphoria.
    Aboujaoude E; Gamel N; Koran LM
    J Clin Psychiatry; 2004 May; 65(5):725-6. PubMed ID: 15163267
    [No Abstract]   [Full Text] [Related]  

  • 33. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment.
    Pearlstein T; Joliat MJ; Brown EB; Miner CM
    Am J Obstet Gynecol; 2003 Apr; 188(4):887-95. PubMed ID: 12712081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls.
    Eriksson E; Sundblad C; Lisjö P; Modigh K; Andersch B
    Psychoneuroendocrinology; 1992; 17(2-3):195-204. PubMed ID: 1438645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoxetine in the treatment of premenstrual dysphoria.
    Su TP; Schmidt PJ; Danaceau MA; Tobin MB; Rosenstein DL; Murphy DL; Rubinow DR
    Neuropsychopharmacology; 1997 May; 16(5):346-56. PubMed ID: 9109106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.
    Martinez PE; Rubinow DR; Nieman LK; Koziol DE; Morrow AL; Schiller CE; Cintron D; Thompson KD; Khine KK; Schmidt PJ
    Neuropsychopharmacology; 2016 Mar; 41(4):1093-102. PubMed ID: 26272051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased salivary chromogranin A in women with severe negative mood states in the premenstrual phase.
    Matsumoto T; Asakura H; Hayashi T
    J Psychosom Obstet Gynaecol; 2012 Sep; 33(3):120-8. PubMed ID: 22779913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variable dosing of sertraline for premenstrual exacerbation of depression: a pilot study.
    Miller MN; Newell CL; Miller BE; Frizzell PG; Kayser RA; Ferslew KE
    J Womens Health (Larchmt); 2008; 17(6):993-7. PubMed ID: 18681820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial.
    Ramos MG; Hara C; Rocha FL
    Int J Neuropsychopharmacol; 2009 Sep; 12(8):1081-8. PubMed ID: 19250561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
    Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
    Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.